- Report
- October 2024
- 200 Pages
Global
From €3322EUR$3,750USD£2,878GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1772EUR$2,000USD£1,535GBP
- Report
- October 2024
- 318 Pages
Global
From €7042EUR$7,950USD£6,102GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1329EUR$1,500USD£1,151GBP
- Report
- May 2024
- 131 Pages
Global
From €5757EUR$6,499USD£4,988GBP
- Report
- May 2024
- 138 Pages
Global
From €5757EUR$6,499USD£4,988GBP
- Report
- March 2019
- 110 Pages
Global
From €2879EUR$3,250USD£2,495GBP
Duopa is a type of central nervous system (CNS) drug used to treat symptoms of Parkinson's disease. It is a combination of two drugs, carbidopa and levodopa, which are delivered directly into the small intestine via a pump. The drug is designed to provide a steady, continuous dose of the two drugs, which helps to reduce the "off" periods associated with Parkinson's disease. Duopa is a relatively new drug, having been approved by the U.S. Food and Drug Administration in 2015.
Duopa is a part of a larger market of CNS drugs, which includes medications used to treat a variety of neurological conditions, such as Alzheimer's disease, epilepsy, and multiple sclerosis. These drugs are typically used to reduce symptoms, improve quality of life, and slow the progression of the disease.
Companies in the Duopa market include AbbVie, Impax Laboratories, and Teva Pharmaceuticals. Show Less Read more